Journal of Gastric Cancer

The Korean Gastric Cancer Association (대한위암학회)
권호 표지

Clinicopathologic Features and Difference in Prognosis in Synchronous and Metachronous Hepatic Metastases of Gastric Cancer

동시성 및 이시성 간전이 위암의 임상병리학적 특성 및 예후의 차이

  • Kim, Jong-Dae (Department of Surgery, Hanyang University College of Medicine) ;
  • Ha, Tae-Kyung (Department of Surgery, Hanyang University College of Medicine) ;
  • Kwon, Sung-Joon (Department of Surgery, Hanyang University College of Medicine)
  • 김종대 (한양대학교 의과대학 외과학교실) ;
  • 하태경 (한양대학교 의과대학 외과학교실) ;
  • 권성준 (한양대학교 의과대학 외과학교실)
  • Published : 2009.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: The aim of this study was to compare synchronous and metachronous hepatic metastases in patients with gastric cancer to determine clinicopathologic features and differences in prognosis as a function of the timing of the metastasis and the treatment modality rendered. Materials and Methods: Sixty-seven patients who were diagnosed with gastric cancer metastatic to the liver and treated at the Hanyang University Hospital between June 1992 and December 2006 were retrospectively analyzed to study the pertinent clinicopathologic features and effect of treatment methods. Results: There was a significant difference with respect to lymphatic (P=0.041) and vascular invasion (P=0.036) in comparing the clinicopathologic features between the patients with synchronous and metachronous hepatic metastases. The 1-year survival rate and median survival time of patients with gastric cancer and liver metastases were 38.9% and 9.2 months in the entire patient cohort, 30.9% and 9.2 months in the synchronous group, and 44.5% and 9.7 months in the metachronus group, respectively (P=0.436). The group of patients undergoing local treatment (such as surgery and radiologic intervention) followed by systemic chemotherapy, the group of patients receiving systemic chemotherapy only, and the untreated group of patients were compared, and there was no difference between the synchronous and metachronous groups. The synchronous and metachronous groups had high survival rates with local treatment. Conclusion: In patients with gastric cancer and liver metastases, there was no difference in prognosis based on the timing of the hepatic metastases. Independent of the timing of hepatic metastasis, aggressive treatment, such as surgery and radiologic intervention, may help improve the prognosis.

목적: 동시성 및 이시성 간전이 위암환자들을 대상으로 임상병리학적 특성 및 예후의 차이에 대하여 알아보고 치료 방법에 따른 예후에 대하여 알아보고자 하였다. 대상 및 방법: 1992년 6월부터 2006년 12월까지 한양대학교병원 외과예서 치료받은 위암 환자 중 간전이가 발견된 67명의 환자를 대상으로 임상병리학적 특징 및 치료 방법에 대하여 후향적 분석을 시행하였다. 결과: 두 군의 임상병리학적 특성에 대한 비교에서 림프관 침윤 여부(P=0.041)와 혈관 침윤 여부(P=0.036)가 동시성군에서 유의하게 많았다. 전체 간전이 위암환자의 1년 생존율과 중앙생존기간은 38.9%, 9.2개월이며 동시성 간전이군에서는 30.9%. 9.2개월이었고 이시성 간전이군에서는 44.5%, 9.7개월로 두 군 사이에 통계학적으로 유의한 차이는 없었다(P=0.436). 치료 방법을 수술 혹은 영상의학적 중재술 등의 국소적 치료와 전신적 항암화학치료를 병행한 경우, 전신적 항암화학치료만 받은 경우, 치료 받지 않은 경우 등 세 가지로 나누었을 때 동시성 간전이군과 이시성 간전이군 사이에 치료 방법의 차이는 없었으며 두 군 모두에서 국소적 치료를 전신적 치료와 병행하였을 경우 생존율이 높았다(P<0.001). 결론: 간전이 위암에 있어서 간전이 병소의 발생 시점에 따른 예후의 차이는 없을 것으로 생각한다. 또한 간전이 발견 시점과 관계 없이 적응 예가 되는 경우 수술적 치료나 영상의학적 중재술 등의 적극적인 치료가 환자의 예후 향상에 기여할 수 있겠다.

Keywords

References

  1. Park IS, Lee YC, Kim WH, Noh SH, Lee KS, Kim H. Clinicopathologic characteristics of early gastric cancer in Korea. Yonsei Med J 2000;41:607-614. https://doi.org/10.3349/ymj.2000.41.5.607
  2. Roukos DH. Current advances and changes in treatment strategy may improve survival and quality of life in patients with potentially curable gastric cancer. Ann Surg Oncol 1999;6:46-56. https://doi.org/10.1007/s10434-999-0046-z
  3. Ministry of Health and Welfare of Korea. Annual Report of a National Enterprise of Cancer Registration. Seoul: Ministry of Health and Welfare of Korea, 2005.
  4. Kim YI, Noh SH, Lee WJ, Min JS. Recurrence pattern & prognosis after curative resection of gastric cancer. J Korean Surg Soc 1996;50:467-474.
  5. Kim SK, Noh SH, Yoo CH, Kim YI, Min JS, Lee KS. Characteristics and prognosis in gastric cancer with liver metastasis. J Korean Cancer Assoc 1997;29:1085-1093.
  6. Shiraishi N, Sato K, Yasuda K, Inomata M, Kitano S. Multivariate prognostic study on large gastric cancer. J Surg Oncol 2007;96:14-18. https://doi.org/10.1002/jso.20631
  7. Takeda J, Yasumoto K, Yano S, Tanaka T, Koufuji K, Hashimoto K, Kakegawa T. Retrospective studies of gastric cancer with hepatic metastases. Kurume Med J 1990;37:271-276. https://doi.org/10.2739/kurumemedj.37.271
  8. Fujimoto S, Shrestha RD, Kasanuki J, Kokubun M, Ichiki N, Miyazaki A, Ohta M, Okui K. Gastric cancer with syn chronous unresectable hepatic metastasis and a positive response to chemotherapy-report of two cases. Jpn J Surg 1987; 17:307-311. https://doi.org/10.1007/BF02470706
  9. Mai M, Ohta T, Minamoto T, Takahashi Y. Comparative study on biological difference between gastric cancer and colorectal cancer. Nippon Geka Gakkai Zasshi 1996;97:263-268.
  10. Kosaka T, Imaizumi H, Kamei K, Usami K, Nakano Y, Ueno K, Takashima S. A case of gastric cancer patient with liver metastasis treated by radiofrequency ablation therapy combined with intra-arterial chemotherapy. Gan To Kagaku Ryoho 2004;31:1737-1739.
  11. Yamakado K, Nakatuka A, Takaki T, Mori Y, Tonouci H, Kusunoki M, Kida H, Takeda K. Prospective study of arterial infusion chemotherapy followed by radiofrequency ablation for the treatment of liver metastasis of gastric cancer. J Vasc Interv Radiol 2005;16:1747-1751. https://doi.org/10.1097/01.RVI.0000188738.84911.3B
  12. Fong Y, Cohen AM, Fortner JG, Enker WE, Turnbull AD, Coit DG, Marrero AM, Prasad M, Blumgart LH, Brennan MF. Liver resection for colorectal metastases. J Clin Oncol 1997;15:938-946. https://doi.org/10.1200/JCO.1997.15.3.938
  13. Tsai MS, Su YH, Ho MC, Liang JT, Chen TP, Lai HS, Lee PH. Clinicopathological features and prognosis in resectable synchronous and metachronous colorectal liver metastasis. Ann Surg Oncol 2007;14:786-794. https://doi.org/10.1245/s10434-006-9215-5
  14. Ambiru S, Miyazaki M, Ito H, Nakagawa K, Shimizu H, Yoshidome H, Shimizu Y, Nakajima N. Benefits and limits of hepatic resection for gastric metastases. Am J Surg 2001;181:279-283. https://doi.org/10.1016/S0002-9610(01)00567-0
  15. Okano K, Maeba T, Ishimura K, Karasawa Y, Goda F, Wakabayashi H, Usuki H, Maeta H. Hepatic resection for metastatic tumors from gastric cancer. Ann Surg 2002;235:86-91. https://doi.org/10.1097/00000658-200201000-00011
  16. Sakamoto Y, Ohyama S, Yamamoto J, Yamada K, Seki M, Ohta K, Kokudo N, Yamaguchi T, Muto T, Makuuchi M. Surgical resection of liver metastases of gastric cancer: an analysis of a 17-year experience with 22 patients. Surgery. 2003;133:507-511. https://doi.org/10.1067/msy.2003.147
  17. Sakamoto Y, Sano T, Shimada K, Esaki M, Saka M, Fukagawa T, Katai H, Kosuge T, Sasako M. Favorable indications for hepatectomy in patient with liver metastasis from gastric cancer. J Surg Oncol 2007;95:534-539. https://doi.org/10.1002/jso.20739
  18. Ueda K, Iwahashi M, Nakamori M, Nakamura M, Naka T, Ishida K, Ojima T, Yamaue H. Analysis of the prognostic factors and evaluation of surgical treatment for synchronous liver metastases from gastric cancer. Langenbecks Arch Surg 2009;394:647-653. https://doi.org/10.1007/s00423-008-0311-9
  19. Thelen A, Jonas S, Benckert C, Lopez-Hänninen E, Neumann U, Rudolph B, Schumacher G, Neuhaus P. Liver resection for metastatic gastric cancer. Eur J Surg Oncol 2008;34:1328-1334. https://doi.org/10.1016/j.ejso.2008.01.022
  20. Lee JH, Bae JS, Ryu KW, Lee JS, Park SR, Kim CG, Kook MC, Choi IJ, Kim YW, Park JG, et al. Gastric cancer patients at high-risk of having synchronous cancer. World J Gastroenterol 2006;16:2588-2592.
  21. Miyazaki M, Itoh H, Nakagawa K, Ambiru S, Shimizu H, Togawa A, Shiobara M, Ohtsuka M, Sasada K, Shimizu Y, et al. Hepatic resection of liver metastases from gastric carcinoma. Am J Gastroenterol 1997;92:490-493.
  22. Zacherl J, Zacherl M, Scheuba C, Steininger R, Wenzl E, Muhlbacher F, Jakesz R, Langle F. Analysis of hepatic resection of metastasis originating from gastric adenocarcinoma. J Gastrointest Surg 2002;6:682-689. https://doi.org/10.1016/S1091-255X(01)00075-0
  23. Shirabe K, Shimada M, Matsumata T, Higashi H, Yakeishi Y, Wakiyama S, Ikeda Y, Ezaki T, Fukuzawa S, Takenaka K, et al. Analysis of the prognostic factors for liver metastasis of gastric cancer after hepatic resection: a multi-institutional study of the indications for resection. Hepatogastroenterology 2003; 50:1560-1563.
  24. Roh HR, Suh KS, Lee HJ, Yang HK, Choe KJ, Lee KU. Outcome of hepatic resection for metastatic gastric cancer. Am Surg 2005;71:95-99.
  25. Fujii K, Fujioka S, Kato K, Machiki Y, Kutsuna Y, Ishikawa A, Takamizawa J, Ko K, Yoshida K, Nimura Y. Resection of liver metastasis from gastric adenocarcinoma. Hepatogastroenterology 2001;48:368-371.
  26. Ochiai T, Sasako M, Mizuno S, Kinoshita T, Takayama T, Kosuge T, Yamazaki S, Maruyama K. Hepatic resection for metastatic tumours from gastric cancer: analysis of prognostic factors. Br J Surg 1994;81:1175-1178. https://doi.org/10.1002/bjs.1800810832
  27. Okuyama K, Isono K, Juan IK, Onoda S, Ochiai T, Yamamoto Y, Koide Y, Satoh H. Evaluation of treatment for gastric cancer with liver metastasis. Cancer 1985;55:2498-2505. https://doi.org/10.1002/1097-0142(19850515)55:10<2498::AID-CNCR2820551032>3.0.CO;2-S
  28. Saiura A, Umekita N, Inoue S, Maeshiro T, Miyamoto S, Matsui Y, Asakage M, Kitamura M. Clinicopathological features and outcome of hepatic resection for liver metastasis from gastric cancer. Hepatogastroenterology 2002;49:1062-1065.
  29. Bentrem DJ, Dematteo RP, Blumgart LH. Surgical therapy for metastatic disease to the liver. Annu Rev Med 2005;56:139-156. https://doi.org/10.1146/annurev.med.56.082103.104630
  30. Liu LX, Zhang WH, Jiang HC. Current treatment for liver metastases from colorectal cancer. World J Gastroenterol 2003;9:193-200. https://doi.org/10.3748/wjg.v9.i2.193